HF
CRNX icon

HRT Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

HRT Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,913
Closed -$459K – 2437
2023
Q4 		$459K Buy
+12,913
New +$396K ﹤0.01% 1411
2022
Q2 		– Sell
-12,848
Closed -$282K – 3041
2022
Q1 		$282K Buy
+12,848
New +$260K ﹤0.01% 2275
2020
Q1 		– Sell
-10,582
Closed -$265K – 862
2019
Q4 		$265K Buy
+10,582
New +$201K 0.01% 800

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HRT Financial's CRNX Position: Q1 2024 in Review

HRT Financial sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 12,913 shares — an estimated $459K sold.

HRT Financial first reported a position in CRNX in Q4 2019 and held it in 3 quarters. The position peaked at $459K in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • HRT Financial reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 12,913 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $459K.
  • HRT Financial first reported a position in Crinetics Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • HRT Financial's Crinetics Pharmaceuticals position peaked at $459K in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.